Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Plasma transforming growth factor β1 and platelet activation: implications for studies in transplant recipients

2001; Oxford University Press; Volume: 16; Issue: 2 Linguagem: Inglês

10.1093/ndt/16.2.361

ISSN

1460-2385

Autores

Beatrice Coupes, Shelley Williams, Ian Roberts, Colin D. Short, Paul Brenchley,

Tópico(s)

Oral and gingival health research

Resumo

Background. Evidence from animal models supports the hypothesis that dysregulated transforming growth factor β1 (TGFβ1) expression plays a role in chronic allograft rejection, the progression of diabetic nephropathy and fibrotic glomerulopathies. However, more evidence is required to support this hypothesis in man, and the current literature concerning blood TGFβ1 levels in clinical studies is highly confused. We have investigated: (i) the hypothesis that the widespread practice of activating clinical samples prior to measurement of TGFβ1 is detecting the platelet‐released pool of TGFβ1, artefactually generated on venepuncture and unrepresentative of the real circulating in vivo TGFβ1 pool; and (ii) the effect of different immunosuppressive drugs on apparent TGFβ1 plasma levels.

Referência(s)